Paul Hudson, Sanofi CEO (Raphael Lafargue/Abaca/Sipa USA; Sipa via AP Images)
September 8, 2021 04:57 AM EDTUpdated 09:15 AM
Deals

Sanofi picks up Kad­mon and its trans­plant drug in $1.9B buy­out, giv­ing Sam Wak­sal 2 Big Phar­ma buy­outs un­der his belt

Amber Tong

It’s not just hot spaces that Paul Hud­son wants Sanofi to lead in.

The CEO’s lat­est, $1.9 bil­lion M&A gam­ble points straight to Kad­mon …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

A service from the Financial Times